SCHEMBL14616800

SCHEMBL14616800

COCCn1c(-c2cnc(-c3ccc4scnc4c3)[nH]2)nc2ccc(Cl)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.53
▸ CASR P41180 1/20 0.37
▸ RAB9A P51151 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HSD17B10 Q99714 4/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ HPGD P15428 2/20 0.36
▸ ALDH1A1 P00352 4/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PTGER4 P35408 3/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ GRM5 P41594 1/20 0.34
▸ CYP1A2 P05177 3/20 0.34
▸ CYP3A4 P08684 3/20 0.34
▸ CYP2C9 P11712 3/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ CASP1 P29466 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14616831 0.91 RIPK2 (0.47) RIPK2CASRRAB9AKMT2AHSD17B10
SCHEMBL14616801 0.89 RIPK2 (0.49) RIPK2CASRRAB9AKMT2AHSD17B10
SCHEMBL14616796 0.86 RIPK2 (0.53) RIPK2CASRRAB9AHSD17B10KDM4E
SCHEMBL14642858 0.85 RIPK2 (0.52) RIPK2RAB9APTGER4ALOX15NPC1
SCHEMBL2551655 0.84 RIPK2 (0.37) RIPK2CASRRAB9AMEN1MAPT
SCHEMBL14616799 0.84 RIPK2 (0.51) RIPK2CASRHSD17B10KDM4ERECQL
SCHEMBL14616792 0.84 RIPK2 (0.43) RIPK2RAB9AHSD17B10KDM4ERECQL
SCHEMBL14616834 0.84 RIPK2 (0.44) RIPK2RAB9AHSD17B10KDM4ERECQL
SCHEMBL14616793 0.83 RIPK2 (0.44) RIPK2CASRRAB9AKMT2AHSD17B10
SCHEMBL14616794 0.83 RIPK2 (0.44) RIPK2RAB9AMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885CASR 2479/4885RAB9A 1002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback